Treatment Variables
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on Androgen Deprivation Therapy (ADTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on Androgen Deprivation Therapy (ADTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on Androgen Deprivation Therapy (ADTX), and no end date is entered (ADTXSTOPDATE) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on hormonal therapy (HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on hormonal therapy (HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on hormonal therapy (HORMONTX), and no end date is entered (HORMONTXSTOPDATE) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on chemotherapy (CHEMOTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on chemotherapy (CHEMOTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on chemotherapy (CHEMOTX), and no end date is entered (CHEMOTXSTOPDATE) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on immunotherapy (IMMUNOTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on immunotherapy (IMMUNOTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on immunotherapy (IMMUNOTX), and no end date is entered (IMMUNOTXSTOPDATE) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on radiopharmaceuticals (RADIOPHARM) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on radiopharmaceuticals (RADIOPHARM) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on radiotherapy (RADIOTX), and no end date is entered (RADIOTXSTOPDATE) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
Could be one of the following procedures: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
Could be one of the following procedures: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
Could be one of the following procedures: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
Could be one of the following procedures: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
Could be one of the following procedures: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
INCLUSION CRITERIA: All patients, If answered 'TURP' on interventions for complications due to local progression (LOCPROGTX_1) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'ureteral stent' on interventions for complications due to local progression (LOCPROGTX_2) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'percutaneous nephrostomy tube' on interventions for complications due to local progression (LOCPROGTX_3) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'suprapubic catheter placement' on interventions for complications due to local progression (LOCPROGTX_4) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'chronic foley catheter / self intermittent catheterization' on interventions for complications due to local progression (LOCPROGTX_5) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on bisphosphonates or denosumab (BISPHOSTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on bisphosphonates or denosumab (BISPHOSTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on bisphosphonates or denosumab (BISPHOSTX), and no end date is entered (BISPHOSTXSTOPDATE) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Single Answer
integer
Acute Complications of Treatment
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy, If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Multiple answer
boolean
INCLUSION CRITERIA: Patients with systemic therapy, If answered 'Other' on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_888) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Free Text RESPONSE OPTIONS: CTCAE grade III-IV complication due to systemic therapy (excluding ADT)
text
INCLUSION CRITERIA: Patients with systemic therapy, If answered Cytopenias on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_1) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: Patients with systemic therapy, If answered Infection on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_2) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: Patients with systemic therapy, If answered Vomiting, diarrhea, constipation, other GI toxicity on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_3) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: Patients with systemic therapy, If answered Neuropathy on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_4) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: Patients with systemic therapy, If answered Cardiovascular toxicity on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_ 5) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: Patients with systemic therapy, If answered Other on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS_888) TIMING: Update at least annually REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
Degree of Health
ECOG / WHO scale: - PS = 0 normal activity level; - PS = 1 restricted with strenuous activity, but can do light activity; - PS = 2 active >/= 50% of day; - PS = 3 spends >50% of day in chair or bed; - PS = 4 totally confined to bed INCLUSION CRITERIA: All patients TIMING: Baseline, 1 year post initiation of treatment, Tracked ongoing annually for life REPORTING SOURCE: Clinical TYPE: Single Answer
integer
Survival and disease control
procedures for local progression: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients, If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
boolean
procedures for local progression: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients, If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
boolean
procedures for local progression: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients, If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
boolean
procedures for local progression: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients, If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
boolean
procedures for local progression: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients, If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
boolean
procedures for local progression: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients, If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
boolean
INCLUSION CRITERIA: All patients TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on symptomatic skeletal related event (SSRE) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life, (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: Patients without known metastasis TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: Patients without known metastasis, If answered 'yes' on development of metastasis (METADEV) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
Castration-resistant disease is defined as two successive PSA rises at least one week apart, or the development or progression of radiographically proven metastatic lesions, in the setting of castrate levels of testosterone (<50 ng/mL) INCLUSION CRITERIA: Patients that are not yet castration resistant TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: Patients that are not yet castration resistant, If answered 'yes' on development of castration-resistant disease (CRPCDATE) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Administrative data (Death registry) TYPE: Single answer
integer
INCLUSION CRITERIA: All patients, If answered 'yes' on overall survival (OVERALLSURV) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Administrative data (Death registry) TYPE: Date by DD/MM/YYYY
date
INCLUSION CRITERIA: All patients, If answered 'yes' on overall survival (OVERALLSURV) TIMING: 1 year post initiation of treatment, Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Administrative data (Death registry) TYPE: Single answer
integer